Skip to main content

Impact of rhomboid intercostal plane block on chronic pain incidence and acute pain scores after oncologic breast surgery: a randomized controlled trial

In brief

A nerve block lowered chronic pain after breast cancer surgery from 31% to 17%

In this randomized trial, chronic pain at 3 months affected 17% of women who received a preoperative rhomboid intercostal plane block, compared with 31% given standard analgesia alone; the block group also used fewer opioids in the first 24 hours. Pain remained less common at 6 months, but the single-center study leaves results to be confirmed in broader settings.

Journal
BMC anesthesiology (Q1)
Published
12 August 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Tolga Karaçay, Basak Altiparmak, Sinan Pektas, Cenk Yazkan, Bakiye Ugur
PMID
43000234
DOI
10.1186/s12871-026-04175-2

Why clinicians should know about it

Abstract

BACKGROUND: Persistent chronic pain after oncologic breast surgery remains a major clinical problem, affecting approximately 25-60% of patients and significantly impairing quality of life. Although the rhomboid intercostal plane block (RIB) has been shown to reduce acute postoperative pain, its role in preventing chronic postoperative pain remains inadequately investigated. METHODS: This prospective, single-center, randomized, double-blind, controlled trial included 254 adult women undergoing oncologic breast surgery with or without lymph node dissection. Patients were randomized to receive either a pre-operative ultrasound-guided single-shot RIB using 30 mL of 0.25% bupivacaine or no regional block (control group). All patients received standardized multimodal systemic analgesia. The primary outcome was the incidence of chronic pain at 3 months postoperatively. Secondary outcomes included chronic pain at 6 months, Brief Pain Inventory-Short Form scores at 3 and 6 months, neuropathic pain assessed using the Douleur Neuropathique 4 questionnaire, acute postoperative pain scores, and 24-h postoperative opioid consumption. RESULTS: Of the 254 randomized patients, 247 completed the study. Chronic pain incidence was significantly lower in the RIB group at 3 months (17% vs 31%; p = 0.009) and 6 months (13% vs 30%; p < 0.001), with reduced neuropathic pain at 6 months. The RIB group had lower 24-h opioid consumption than controls (p = 0.01). CONCLUSIONS: Pre-operative single-shot RIB significantly reduced chronic postoperative pain and opioid consumption following oncologic breast surgery, and may be considered as part of multimodal analgesia to decrease chronic pain incidence, neuropathic pain and improve acute postoperative pain control. TRIAL REGISTRATION: Clinicaltrials.gov (NCT06019325 registered August 17, 2023).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.